查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
RNA 治療臨床試驗市場 - 成長、未來前景、競爭分析，2023-2031
市場調查報告書
商品編碼
1340134

RNA 治療臨床試驗市場 - 成長、未來前景、競爭分析，2023-2031

RNA Therapy Clinical Trials Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日期: | 出版商: Acute Market Reports | 英文 110 Pages | 商品交期: 最快1-2個工作天內

價格

由於基於 RNA 的治療方法的進步以及標靶和個人化治療的潛力，RNA 治療臨床試驗市場預計在 2023 年至 2031 年預測期內將以 4% 的複合年增長率增長。RNA療法利用核糖核酸（RNA）分子靶向特定基因並調節蛋白質產生，為治療多種疾病（包括癌症、遺傳性疾病和傳染病）提供了有希望的機會。隨著更多基於 RNA 的療法通過臨床試驗並走向商業化，市場收入預計將繼續呈上升趨勢。對個人化醫療的需求不斷增長，有可能治療以前無法治療的疾病，也促進了市場的擴張。RNA 治療領域正在進行的臨床試驗對於評估這些創新療法的安全性和有效性至關重要。隨著更多臨床數據的出現，監管機構對基於 RNA 的藥物的批准可能會增加，為臨床實踐中更廣泛的採用鋪平道路。總而言之，在基於RNA 的療法徹底改變疾病治療並提供個人化有針對性的醫療保健方法的潛力的推動下，RNA 療法臨床試驗市場呈現出令人印象深刻的收入增長和充滿希望的複合年增長率。隨著臨床試驗的進展和更多基於 RNA 的藥物進入市場，RNA 療法將對醫學和患者護理的未來產生重大影響。

RNA治療技術的進展

RNA治療技術的進步是支持RNA治療臨床試驗市場成長的主要因素。更穩定、更有效的遞送系統（例如脂質奈米顆粒和病毒載體）的開發改善了基於 RNA 的治療藥物向目標組織和細胞的遞送。此外，RNA合成和修飾技術的創新正在提高RNA分子的穩定性和特異性，使它們能夠更有效地針對致病基因。這些技術進步擴大了 RNA 療法的潛在應用，並導致探索其在治療多種疾病中的用途的臨床試驗激增。《Nature Communications》上發表的一項研究報告了使用脂質奈米粒子成功遞送 mRNA 療法，顯示出臨床前模型中穩定性和治療效果的改善。《Journal of Controlled Release》上發表的另一項研究強調了使用自擴增 mRNA 作為疫苗平台，並在動物模型中證明了對感染的強大免疫反應。這些例子顯示了 RNA 療法的技術進步如何促進臨床試驗的進展並增加治療成功的可能性。

慢性病和遺傳性疾病盛行率上升

慢性病和遺傳疾病的盛行率不斷上升，刺激了對創新和標靶治療的需求，並推動了 RNA 治療臨床試驗的成長。基於 RNA 的療法透過針對特定的致病基因和調節蛋白質的產生，提供了解決以前無法治療的疾病的潛力。癌症、罕見遺傳疾病和神經退化性疾病等疾病正在成為基於 RNA 的治療的重要標靶。迫切需要找到針對這些疾病的有效治療方法，導致研究 RNA 療法的安全性和有效性的臨床試驗激增，將其定位為未來醫療幹預的有希望的途徑。美國癌症協會報告稱，癌症仍然是全世界死亡的主要原因之一，這促使人們大力開展研究和臨床工作，以開發標靶療法，包括基於 RNA 的方法。同樣，國家罕見疾病組織 (NORD) 等組織也強調罕見遺傳疾病創新療法的必要性，並增加了對 RNA 療法臨床試驗的興趣和投資。

支持性監管環境

基於 RNA 的療法的支持性監管環境在推動臨床試驗市場的成長中發揮關鍵作用。美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構已經建立了框架和加速途徑，以加快 RNA 療法的開發和批准。這些途徑將加速有前景的基於 RNA 的療法的臨床開發和審查，減少將這些療法推向市場的時間和成本。監管支援正在鼓勵更多製藥和生物技術公司投資 RNA 療法開發，並為擴大該領域的臨床試驗做出貢獻。FDA 批准了第一個基於 ASO 的基於 RNA 的治療藥物，用於治療特定的遺傳疾病，這證明了 RNA 治療藥物的支持性監管環境。此外，針對基於 RNA 的治療的具體監管指南和加速途徑的製定表明了監管機構促進該領域創新的承諾。

交付和定位挑戰

影響 RNA 療法臨床試驗市場的重要限制因素之一是與基於 RNA 的療法的遞送和標靶相關的挑戰。RNA 分子本質上不穩定，容易被細胞內酵素降解，這會限制其功效和治療潛力。此外，有效地將 RNA 療法傳遞到特定的目標組織和細胞仍然是一個主要障礙。遞送系統必須保護 RNA 分子免於降解，讓它們穿過生物屏障，並允許有效地攝取到目標細胞中。此外，實現精確標靶對於避免脫靶效應和潛在副作用至關重要。開發安全有效的遞送載體，將 RNA 治療藥物精確地遞送至所需的作用位點，仍然是 RNA 治療領域中一個複雜且持續的挑戰。《Journal of Controlled Release》上發表的一項研究強調了使用奈米粒子提供基於 RNA 的治療方法所面臨的挑戰，並強調了穩定性和控釋方面的問題。此外，《Nature Reviews Drug Discovery》上發表的一篇綜述強調，遞送和標靶障礙是 RNA 療法臨床應用的關鍵瓶頸，影響治療效果和整體成功。這些例子強調了解決與遞送和標靶相關的挑戰的重要性，以最大限度地發揮基於 RNA 的療法在臨床試驗中的潛力。

信使 RNA (mRNA) 領域繼續主導成長和收入

在 RNA 治療臨床試驗市場的各個模式領域中，信使 RNA (mRNA) 領域預計將在 2023-2031 年預測期內表現出最高的複合年增長率，並在 2022 年實現最高收入。我做到了。基於 mRNA 的療法前景廣闊，因為它們直接編碼體內的特定蛋白質，為疫苗開發、癌症免疫療法和蛋白質替代療法提供了潛在的應用。mRNA 引發針對病原體的標靶免疫反應的能力正在引起人們對探索其治療潛力的臨床試驗的極大興趣和投資，基於 mRNA 的 COVID-19 疫苗的成功開發證明了這一點。此外，反義療法領域的複合年增長率和收入也顯示出顯著成長。反義療法透過針對特定的 RNA 分子來調節蛋白質的產生，使其特別適合治療遺傳性疾病和某些類型的癌症。反義療法的發展正在迅速進展，多項臨床試驗已顯示出針對多種疾病的潛在功效。RNA幹擾（RNAi）領域是RNA治療臨床試驗中發展緩慢但不可或缺的療法。基於 RNAi 的療法抑制特定基因的表達，為標靶致病基因提供了一種有前景的方法。最後，寡核甘酸、非反義、非 RNAi 領域也在穩定成長，包括不屬於傳統反義或 RNAi 類別的基於 RNA 的創新療法。

從臨床試驗階段來看，III期試驗佔市場主導地位

在RNA療法臨床試驗市場中，臨床試驗階段是決定RNA療法進展和成功的關鍵因素。在各階段中，III期試驗部分預計在2023-2031年預測期間呈現最高複合年增長率，並在2022年產生最高收入。III 期試驗旨在納入更多患者，並評估 RNA 療法與現有標準療法或安慰劑相比的安全性和有效性。III 期試驗的正面結果將導致基於 RNA 的療法獲得監管批准和商業化。因此，III期臨床試驗的高獲利和高成長得益於藥廠在後期臨床開發上的大量投資。此外，二期試驗的複合年增長率和收入也出現了顯著增長。II 期試驗評估 RNA 療法在更大患者群體中的治療效果和劑量，並為支持 RNA 療法向 III 期試驗的過渡提供重要數據。隨著基於 RNA 的療法的臨床開發的進展，對 II 期試驗的需求增加，促進了市場的驚人成長。I 期試驗（包括在少數健康志願者中進行 RNA 療法的早期試驗）顯示出適度的增長。這些臨床試驗的重點是評估RNA療法的安全性和劑量範圍，並為後續步驟奠定基礎發揮至關重要的作用。最後，第四階段試驗正在穩定成長。IV 期試驗，也稱為上市後監測試驗，評估 RNA 療法在現實臨床環境中的長期安全性和有效性。這些試驗提供了有關基於 RNA 的療法在受控臨床試驗環境之外的性能的寶貴數據，並確保其在廣泛使用期間持續安全性和有效性。總體而言，III 期試驗的複合年增長率和銷售額最高，反映出它們在基於 RNA 的療法的成功商業化和採用中發揮的關鍵作用。

亞太地區在預測期內蘊藏著巨大的機會

北美成為表現突出的市場，RNA 治療臨床試驗的銷售百分比最高。該地區強大的市場地位歸功於主要製藥和生物技術公司的存在，這些公司正在大力投資基於 RNA 的療法。此外，成熟的醫療基礎設施、支持性監管環境和慢性病的高盛行率正在推動北美對 RNA 治療臨床試驗的需求。同時，亞太地區的RNA治療臨床試驗市場複合年增長率(CAGR)最高。該地區的成長得益於政府加強臨床研究措施、醫療保健支出增加以及對精準醫療的日益關注等因素。此外，亞太地區龐大且多樣化的患者群體為研究基於 RNA 的療法在各種疾病中的有效性和安全性的臨床試驗提供了巨大的機會。歐洲的收入排名第二，僅次於北美，其強大的研究基礎設施和對創新療法日益增長的興趣推動了 RNA 療法臨床試驗的需求。此外，由於醫療基礎設施的改善和醫學研究投資的增加，中東、非洲和拉丁美洲地區的 RNA 治療臨床試驗也出現了小幅增長。

研發投資在大公司的重要性日益增加

RNA治療臨床試驗市場在製藥和生物技術行業的主要參與者中競爭非常激烈。這些公司處於開發基於 RNA 的創新療法並進行臨床試驗以評估其安全性和有效性的前沿。這項競爭格局的主要參與者包括 Moderna Therapeutics、BioNTech SE、Arrowhead Pharmaceuticals、Alnylam Pharmaceuticals 和 Ionis Pharmaceuticals。這些公司已成為 RNA 治療的領導者，擁有針對多種疾病（包括癌症、遺傳性疾病和傳染病）的基於 RNA 的治療藥物的強大產品線。在這種競爭環境中，領先公司採取了多種策略來鞏固自己的地位並推動 RNA 治療臨床試驗的進步。其中一項關鍵策略著重於研發（R&D）投資。領先的公司正在投入大量資源來發現和開發基於 RNA 的新型療法。這包括投資尖端 RNA 合成和遞送技術、提高 RNA 分子的穩定性和特異性，以及探索 mRNA 和 RNA 幹擾 (RNAi) 療法等新療法。此外，市場參與者也在探索新興市場的機會，並尋求擴大其全球足跡。亞太地區由於其龐大的患者群體和不斷增加的醫療保健投資而具有巨大的成長潛力。主要參與者正在這些地區建立合作夥伴關係並進行臨床試驗，以滿足對基於 RNA 的創新療法不斷增長的需求。總體而言，RNA 治療臨床試驗市場的競爭趨勢的特徵是強大的研發投資、策略聯盟、監管參與以及對全球擴張的關注。該市場的領先公司致力於推動 RNA 治療領域的發展，將有前景的臨床試驗結果轉化為經批准且商業上成功的治療方法。隨著臨床試驗的進展以及更多基於RNA的藥物走向商業化，RNA治療臨床試驗市場將持續成長和變革，為多種疾病的個人化和標靶治療的進步做出貢獻，令人期待。

目錄

第一章 前言

  • 報告內容
    • 報告目的
    • 目標聽眾
    • 主要提供產品
  • 市場細分
  • 調查方法
    • 第一階段—二次調查
    • 第二階段-初步調查
    • 第三階段-專家評審
    • 先決條件
    • 採取的方法

第二章執行摘要

第三章 RNA治療臨床試驗市場：競爭分析

  • 主要供應商的市場地位
  • 供應商採取的策略
  • 主要產業戰略
  • 等級分析：2022 年與 2031 年

第四章 RNA治療臨床試驗市場：宏觀分析與市場動態

  • 介紹
  • 2021-2031年全球RNA治療臨床試驗市場價值
  • 市場動態
    • 市場驅動力
    • 市場製約因素
    • 主要問題
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析

第五章 RNA 治療臨床試驗市場：依模式 2021-2031

  • 市場概況
  • 成長/利潤分析：2022 年與 2031 年
  • 市場細分
    • RNA干擾
    • 反義療法
    • 信差核糖核酸
    • 寡核甘酸非反義非RNAi

第六章 RNA 治療臨床試驗市場：依臨床試驗階段劃分 2021-2031

  • 市場概況
  • 成長/利潤分析：2022 年與 2031 年
  • 市場細分
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段

第七章 RNA 治療臨床試驗市場：依治療領域 2021-2031

  • 市場概況
  • 成長/利潤分析：2022 年與 2031 年
  • 市場細分
    • 罕見疾病
    • 抗感染
    • 抗癌劑
    • 神經系統
    • 消化系統/代謝系統
    • 肌肉骨骼系統
    • 心血管、呼吸系統
    • 情懷
    • 其他

第八章北美RNA治療臨床試驗市場2021-2031

  • 市場概況
  • RNA 治療臨床試驗市場：依模式 2021-2031
  • RNA 治療臨床試驗市場：依臨床試驗階段 2021-2031
  • RNA 治療臨床試驗市場：依治療領域 2021-2031
  • RNA 治療臨床試驗市場：依地區劃分 2021-2031
    • 北美
      • 美國
      • 加拿大
      • 其他北美

第九章英國及歐盟RNA治療臨床試驗市場2021-2031

  • 市場概況
  • RNA 治療臨床試驗市場：依模式 2021-2031
  • RNA 治療臨床試驗市場：依臨床試驗階段 2021-2031
  • RNA 治療臨床試驗市場：依治療領域 2021-2031
  • RNA 治療臨床試驗市場：依地區劃分 2021-2031
    • 英國和歐盟
      • 英國
      • 德國
      • 西班牙
      • 意大利
      • 法國
      • 歐洲其他地區

第十章亞太RNA治療臨床試驗市場2021-2031

  • 市場概況
  • RNA 治療臨床試驗市場：依模式 2021-2031
  • RNA 治療臨床試驗市場：依臨床試驗階段 2021-2031
  • RNA 治療臨床試驗市場：依治療領域 2021-2031
  • RNA 治療臨床試驗市場：依地區劃分 2021-2031
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 亞太其他地區

第十一章拉丁美洲RNA治療臨床試驗市場2021-2031

  • 市場概況
  • RNA 治療臨床試驗市場：依模式 2021-2031
  • RNA 治療臨床試驗市場：依臨床試驗階段 2021-2031
  • RNA 治療臨床試驗市場：依治療領域 2021-2031
  • RNA 治療臨床試驗市場：依地區劃分 2021-2031
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地區

第十二章中東與非洲RNA治療臨床試驗市場2021-2031

  • 市場概況
  • RNA 治療臨床試驗市場：依模式 2021-2031
  • RNA 治療臨床試驗市場：依臨床試驗階段 2021-2031
  • RNA 治療臨床試驗市場：依治療領域 2021-2031
  • RNA 治療臨床試驗市場：依地區劃分 2021-2031
    • 中東/非洲
      • GCC
      • 非洲
      • 其他中東/非洲地區

第十三章公司簡介

  • Moderna Therapeutics
  • BioNTech SE
  • Arrowhead Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Ionis Pharmaceuticals
  • 其他主要公司
Product Code: 139742-07-23

The RNA therapy clinical trials market is expected to witness a CAGR of 4% during the forecast period of 2023 to 2031, driven by advancements in RNA-based therapeutic approaches and the potential for targeted and personalized treatments. RNA therapy involves the use of ribonucleic acid (RNA) molecules to target specific genes and modulate protein production, offering promising opportunities for treating various diseases, including cancer, genetic disorders, and infectious diseases. The market's revenue is expected to continue its upward trajectory as more RNA-based therapies progress through clinical trials and move toward commercialization. The potential to address previously untreatable diseases and the growing demand for personalized medicine has also contributed to the market's expansion. The ongoing clinical trials in the RNA therapy field are essential for evaluating the safety and efficacy of these innovative therapies. As more clinical data become available, regulatory approvals for RNA-based drugs are likely to increase, paving the way for their wider adoption in clinical practice. In conclusion, the RNA therapy clinical trials market has shown impressive revenue growth and a promising CAGR, driven by the potential of RNA-based therapies to revolutionize disease treatment and offer personalized, targeted approaches to healthcare. As clinical trials progress and more RNA-based drugs enter the market, RNA therapy is poised to have a significant impact on the future of medicine and patient care.

Advancements in RNA Therapeutic Technologies

Advancements in RNA therapeutic technologies have been a major driver behind the growth of the RNA therapy clinical trials market. The development of more stable and efficient delivery systems, such as lipid nanoparticles and viral vectors, has improved the delivery of RNA-based therapies to target tissues and cells. Additionally, innovations in RNA synthesis and modification techniques have enhanced the stability and specificity of RNA molecules, enabling more effective targeting of disease-causing genes. These technological advancements have expanded the potential applications of RNA therapies, leading to a surge in clinical trials exploring their use in treating a wide range of diseases. A study published in Nature Communications reported on the successful delivery of mRNA therapeutics using lipid nanoparticles, showing increased stability and therapeutic efficacy in preclinical models. Another study in the Journal of Controlled Release highlighted the use of self-amplifying mRNA as a vaccine platform, demonstrating robust immune responses against infectious diseases in animal models. These examples demonstrate how technological advancements in RNA therapeutics are driving progress in clinical trials and increasing the potential for successful treatments.

Rising Prevalence of Chronic and Genetic Diseases

The increasing prevalence of chronic and genetic diseases has fueled the demand for innovative and targeted therapies, thus driving the growth of RNA therapy clinical trials. RNA-based therapies offer the potential to address previously untreatable diseases by targeting specific disease-causing genes and modulating protein production. Conditions such as cancer, rare genetic disorders, and neurodegenerative diseases have emerged as key targets for RNA-based therapeutics. The urgency to find effective treatments for these diseases has led to a surge in clinical trials investigating the safety and efficacy of RNA therapies, positioning them as a promising avenue for future medical interventions. The American Cancer Society reported that cancer remains one of the leading causes of death worldwide, leading to significant research and clinical efforts to develop targeted therapies, including RNA-based approaches. Similarly, organizations such as the National Organization for Rare Disorders (NORD) emphasize the need for innovative therapies for rare genetic diseases, driving increased interest and investment in RNA therapy clinical trials.

Supportive Regulatory Environment

The supportive regulatory environment for RNA-based therapies has played a crucial role in driving the growth of the clinical trials market. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established frameworks and expedited pathways to facilitate the development and approval of RNA therapies. These pathways allow for accelerated clinical development and review of promising RNA-based treatments, reducing the time and cost required to bring these therapies to the market. The regulatory support has encouraged more pharmaceutical and biotechnology companies to invest in RNA therapy development and has contributed to the expansion of clinical trials in this field. The FDA's approval of the first RNA-based therapeutic, an ASO-based drug for the treatment of a specific genetic disorder, stands as a testament to the supportive regulatory environment for RNA therapies. Additionally, the creation of regulatory guidelines and expedited pathways specifically tailored for RNA-based therapeutics demonstrates the commitment of regulatory agencies to foster innovation in this field.

Challenges in Delivery and Targeting

One significant restraint impacting the RNA therapy clinical trials market is the challenges associated with the delivery and targeting of RNA-based therapeutics. RNA molecules are inherently unstable and susceptible to degradation by cellular enzymes, which can limit their efficacy and therapeutic potential. Moreover, effectively delivering RNA therapies to specific target tissues and cells poses a significant obstacle. Delivery systems need to protect RNA molecules from degradation, navigate biological barriers, and ensure efficient uptake by the intended cells. Additionally, achieving precise targeting is essential to avoid off-target effects and potential adverse reactions. Developing safe and effective delivery vehicles that can precisely deliver RNA therapies to the desired sites of action remains a complex and ongoing challenge in the field of RNA therapeutics. A study published in the Journal of Controlled Release highlighted the difficulties in delivering RNA-based therapeutics using nanoparticles, where issues of stability and controlled release were identified. Furthermore, a review published in Nature Reviews Drug Discovery emphasized that delivery and targeting hurdles are critical bottlenecks in the clinical translation of RNA therapies, impacting their therapeutic efficacy and overall success. These examples highlight the importance of addressing the challenges associated with delivery and targeting to unlock the full potential of RNA-based therapies in clinical trials.

Messenger RNA (mRNA) Segment to Continue Dominating Growth and Revenues

Among the various modality segments in the RNA therapy clinical trials market, the Messenger RNA (mRNA) segment is expected to exhibit the highest CAGR during the forecast period of 2023 to 2031 and generated the highest revenue in 2022. mRNA-based therapies hold immense promise as they directly encode specific proteins in the body, offering potential applications in vaccine development, cancer immunotherapy, and protein replacement therapies. The ability of mRNA to trigger a targeted immune response against pathogens, such as seen with the successful development of mRNA-based COVID-19 vaccines, has driven significant interest and investment in clinical trials exploring its therapeutic potential. Additionally, the Antisense therapy segment has also shown substantial growth in both CAGR and revenue. Antisense therapies work by targeting specific RNA molecules to modulate protein production, making them particularly suitable for treating genetic disorders and certain types of cancer. The development of Antisense therapies has progressed rapidly, with several clinical trials showcasing their potential efficacy in various diseases. The RNA interference (RNAi) segment, while experiencing moderate growth, remains an essential modality in RNA therapy clinical trials. RNAi-based therapies interfere with the expression of specific genes, offering a promising approach to target disease-causing genes. Lastly, the Oligonucleotide, non-antisense, non-RNAi segment has also witnessed steady growth, encompassing other innovative RNA-based therapeutic modalities that do not fit within the traditional antisense or RNAi categories.

Phase III Trials to Dominate the Market by Clinical Trial Phase

In the RNA therapy clinical trials market, the Clinical Trials Phase is a crucial factor in determining the progression and success of RNA-based therapies. Among the various phases, the Phase III trials segment is expected to exhibit the highest CAGR during the forecast period of 2023 to 2031 and generated the highest revenue in 2022. Phase III trials involve a larger population of patients and are designed to evaluate the safety and efficacy of RNA therapies in comparison to existing standard treatments or placebos. Positive results from Phase III trials are essential for obtaining regulatory approval and commercialization of RNA-based therapies. Consequently, the high revenue and growth in Phase III trials can be attributed to the significant investments made by pharmaceutical companies in late-stage clinical development. Additionally, Phase II trials have also experienced substantial growth in both CAGR and revenue. Phase II trials assess the therapeutic efficacy and dosing of RNA therapies in a larger patient group, providing critical data to support the advancement of RNA therapeutics into Phase III trials. As RNA-based therapies progress through clinical development, the demand for Phase II trials has increased, contributing to their impressive growth in the market. Phase I trials, which involve the initial testing of RNA therapies in a small group of healthy volunteers, have shown moderate growth. These trials focus on evaluating the safety and dosage range of RNA therapies and play a pivotal role in laying the groundwork for subsequent phases. Lastly, Phase IV trials have experienced steady growth. Also known as post-marketing surveillance trials, Phase IV trials assess the long-term safety and effectiveness of RNA therapies in a real-world setting. These trials provide valuable data on the performance of RNA-based therapies beyond the controlled clinical trial environment, ensuring their continued safety and efficacy during widespread use. Overall, Phase III trials stand out with the highest CAGR and revenue, reflecting their critical role in the successful commercialization and adoption of RNA-based therapies.

APAC to Promise Significant Opportunities during the Forecast Period

North America has emerged as a prominent market, showcasing the highest revenue percentage in RNA therapy clinical trials. The region's strong market position can be attributed to the presence of leading pharmaceutical and biotechnology companies with significant investments in RNA-based therapies. Additionally, well-established healthcare infrastructure, a supportive regulatory environment, and a high prevalence of chronic diseases drive the demand for RNA therapy clinical trials in North America. On the other hand, Asia-Pacific has experienced the highest Compound Annual Growth Rate (CAGR) in the RNA therapy clinical trials market. The region's growth can be attributed to factors such as increasing government initiatives to promote clinical research, rising healthcare expenditure, and a growing focus on precision medicine. Moreover, the large and diverse patient population in Asia-Pacific provides a substantial opportunity for clinical trials investigating the efficacy and safety of RNA-based therapies in different disease contexts. Europe follows North America closely in terms of revenue generation, with a robust research infrastructure and growing interest in innovative therapies fueling the demand for RNA therapy clinical trials. Furthermore, the Middle East and Africa, and Latin America regions are also witnessing moderate growth in RNA therapy clinical trials, driven by improving healthcare infrastructure and rising investments in medical research.

R&D Investments to Become Crucial among the Top Market Players

The RNA therapy clinical trials market is witnessing intense competition among top players in the pharmaceutical and biotechnology industries. These companies are at the forefront of developing innovative RNA-based therapies and conducting clinical trials to assess their safety and efficacy. Some of the key players in this competitive landscape include Moderna Therapeutics, BioNTech SE, Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals, among others. These companies have established themselves as leaders in the RNA therapy field, with a strong pipeline of RNA-based therapeutics targeting various diseases, including cancer, genetic disorders, and infectious diseases. In this competitive environment, key players are employing several strategies to strengthen their position and drive advancements in RNA therapy clinical trials. One of the primary strategies is focused on research and development (R&D) investment. Leading companies are dedicating substantial resources to discovering and developing novel RNA-based therapies. This includes investing in cutting-edge RNA synthesis and delivery technologies, enhancing the stability and specificity of RNA molecules, and exploring new therapeutic modalities, such as mRNA and RNA interference (RNAi) therapies. Furthermore, market players are also exploring opportunities in emerging markets to expand their global footprint. Asia-Pacific, in particular, presents significant growth potential, with a large patient population and increasing healthcare investments. Key players are establishing partnerships and conducting clinical trials in these regions to tap into the rising demand for innovative RNA-based therapies. Overall, the competitive trends in the RNA therapy clinical trials market are characterized by robust R&D investments, strategic collaborations, regulatory engagements, and a focus on global expansion. The key players in the market are committed to advancing the field of RNA therapy and translating promising clinical trial results into approved and commercially successful therapies. As clinical trials progress and more RNA-based drugs move towards commercialization, the RNA therapy clinical trials market is expected to witness further growth and transformation, contributing to the advancement of personalized and targeted therapies for a wide range of diseases.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofRNA Therapy Clinical Trials market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the RNA Therapy Clinical Trials market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Modality

  • RNA interference
  • Antisense therapy
  • Messenger RNA
  • Oligonucleotide, non-antisense, non-RNAi

Clinical Trials Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Therapeutic Areas

  • Rare Diseases
  • Anti-infective
  • Anticancer
  • Neurological
  • Alimentary/Metabolic
  • Musculoskeletal
  • Cardiovascular Respiratory
  • Sensory
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of RNA Therapy Clinical Trials market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the RNA Therapy Clinical Trials market?
  • Which is the largest regional market for RNA Therapy Clinical Trials market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving RNA Therapy Clinical Trials market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the RNA Therapy Clinical Trials market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global RNA Therapy Clinical Trials Market
  • 2.2. Global RNA Therapy Clinical Trials Market, By Modality, 2022 (US$ Million)
  • 2.3. Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2022 (US$ Million)
  • 2.4. Global RNA Therapy Clinical Trials Market, By Therapeutic Areas, 2022 (US$ Million)
  • 2.5. Global RNA Therapy Clinical Trials Market, By Geography, 2022 (US$ Million)
  • 2.6. Attractive Investment Proposition by Geography, 2022

3. RNA Therapy Clinical Trials Market: Competitive Analysis

  • 3.1. Market Positioning of Key RNA Therapy Clinical Trials Market Vendors
  • 3.2. Strategies Adopted by RNA Therapy Clinical Trials Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. RNA Therapy Clinical Trials Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global RNA Therapy Clinical Trials Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. RNA interference
    • 5.3.2. Antisense therapy
    • 5.3.3. Messenger RNA
    • 5.3.4. Oligonucleotide, non-antisense, non-RNAi

6. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Phase I
    • 6.3.2. Phase II
    • 6.3.3. Phase III
    • 6.3.4. Phase IV

7. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Rare Diseases
    • 7.3.2. Anti-infective
    • 7.3.3. Anticancer
    • 7.3.4. Neurological
    • 7.3.5. Alimentary/Metabolic
    • 7.3.6. Musculoskeletal
    • 7.3.7. Cardiovascular Respiratory
    • 7.3.8. Sensory
    • 7.3.9. Others

8. North America RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
  • 8.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
  • 8.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  • 8.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
    • 8.5.1.North America
      • 8.5.1.1. U.S.
        • 8.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 8.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 8.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 8.5.1.2. Canada
        • 8.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 8.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 8.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 8.5.1.3. Rest of North America
        • 8.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 8.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 8.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

9. UK and European Union RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
  • 9.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
  • 9.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  • 9.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
    • 9.5.1.UK and European Union
      • 9.5.1.1. UK
        • 9.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 9.5.1.2. Germany
        • 9.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 9.5.1.3. Spain
        • 9.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 9.5.1.4. Italy
        • 9.5.1.4.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.4.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.4.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 9.5.1.5. France
        • 9.5.1.5.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.5.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.5.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 9.5.1.6. Rest of Europe
        • 9.5.1.6.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.6.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.6.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

10. Asia Pacific RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
  • 10.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
  • 10.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  • 10.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
    • 10.5.1.Asia Pacific
      • 10.5.1.1. China
        • 10.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 10.5.1.2. Japan
        • 10.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 10.5.1.3. India
        • 10.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 10.5.1.4. Australia
        • 10.5.1.4.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.4.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.4.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 10.5.1.5. South Korea
        • 10.5.1.5.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.5.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.5.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 10.5.1.6. Rest of Asia Pacific
        • 10.5.1.6.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.6.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.6.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

11. Latin America RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
  • 11.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
  • 11.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  • 11.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
    • 11.5.1.Latin America
      • 11.5.1.1. Brazil
        • 11.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 11.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 11.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 11.5.1.2. Mexico
        • 11.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 11.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 11.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 11.5.1.3. Rest of Latin America
        • 11.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 11.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 11.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

12. Middle East and Africa RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
  • 12.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
  • 12.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  • 12.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
    • 12.5.1.Middle East and Africa
      • 12.5.1.1. GCC
        • 12.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 12.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 12.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 12.5.1.2. Africa
        • 12.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 12.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 12.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 12.5.1.3. Rest of Middle East and Africa
        • 12.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 12.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 12.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

13. Company Profile

  • 13.1. Moderna Therapeutics
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. BioNTech SE
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. Arrowhead Pharmaceuticals
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. Alnylam Pharmaceuticals
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. Ionis Pharmaceuticals
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Other Notable Players
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 2 Global RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 3 Global RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 4 North America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 5 North America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 6 North America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 7 U.S. RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 8 U.S. RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 9 U.S. RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 10 Canada RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 11 Canada RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 12 Canada RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 13 Rest of North America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 14 Rest of North America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 15 Rest of North America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 16 UK and European Union RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 17 UK and European Union RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 18 UK and European Union RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 19 UK RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 20 UK RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 21 UK RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 22 Germany RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 23 Germany RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 24 Germany RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 25 Spain RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 26 Spain RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 27 Spain RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 28 Italy RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 29 Italy RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 30 Italy RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 31 France RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 32 France RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 33 France RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 34 Rest of Europe RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 35 Rest of Europe RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 36 Rest of Europe RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 37 Asia RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 38 Asia RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 39 Asia RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 40 China RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 41 China RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 42 China RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 43 Japan RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 44 Japan RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 45 Japan RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 46 India RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 47 India RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 48 India RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 49 Australia RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 50 Australia RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 51 Australia RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 52 South Korea RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 53 South Korea RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 54 South Korea RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 55 Latin America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 56 Latin America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 57 Latin America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 58 Brazil RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 59 Brazil RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 60 Brazil RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 61 Mexico RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 62 Mexico RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 63 Mexico RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 64 Rest of Latin America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 65 Rest of Latin America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 66 Rest of Latin America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 67 Middle East and Africa RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 68 Middle East and Africa RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 69 Middle East and Africa RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 70 GCC RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 71 GCC RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 72 GCC RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 73 Africa RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 74 Africa RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 75 Africa RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 76 Rest of Middle East and Africa RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 77 Rest of Middle East and Africa RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 78 Rest of Middle East and Africa RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global RNA Therapy Clinical Trials Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global RNA Therapy Clinical Trials Market: Quality Assurance
  • FIG. 5 Global RNA Therapy Clinical Trials Market, By Modality, 2022
  • FIG. 6 Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2022
  • FIG. 7 Global RNA Therapy Clinical Trials Market, By Therapeutic Areas, 2022
  • FIG. 8 Global RNA Therapy Clinical Trials Market, By Geography, 2022
  • FIG. 9 Market Geographical Opportunity Matrix - Global RNA Therapy Clinical Trials Market, 2022

FIG. 10Market Positioning of Key RNA Therapy Clinical Trials Market Players, 2022

FIG. 11Global RNA Therapy Clinical Trials Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 12 Global RNA Therapy Clinical Trials Market, By Modality, 2022 Vs 2031, %
  • FIG. 13 Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2022 Vs 2031, %
  • FIG. 14 Global RNA Therapy Clinical Trials Market, By Therapeutic Areas, 2022 Vs 2031, %
  • FIG. 15 U.S. RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 16 Canada RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 17 Rest of North America RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 18 UK RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 19 Germany RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 20 Spain RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 21 Italy RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 22 France RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 23 Rest of Europe RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 24 China RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 25 Japan RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 26 India RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 27 Australia RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 28 South Korea RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 29 Rest of Asia RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 30 Brazil RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 31 Mexico RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 32 Rest of Latin America RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 33 GCC RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 34 Africa RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 35 Rest of Middle East and Africa RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031